MF

AM Best Affirms Credit Ratings of MAPFRE Fianzas, S.A.

Thursday, October 14, 2021 - 6:31pm

The outlook of these Credit Ratings (ratings) is stable.

Key Points: 
  • The outlook of these Credit Ratings (ratings) is stable.
  • Such scenarios have been incorporated into the ratings and present a key point for AM Best to review in coming years.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Bests Credit Ratings .
  • For information on the proper use of Bests Credit Ratings, Bests Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Bests Ratings & Assessments .

Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

Thursday, October 14, 2021 - 9:00am

Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).

Key Points: 
  • Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).
  • The best overall response rate (ORR) seen in the real-life study was 47.0% in MF patients and 68.3% in SS patients.
  • In contrast, the ORRb in MAVORIC was 21% and 37%, respectively.1,2 Of the 124 patients who received POTELIGEO treatment in the study, 44% were MF patients and 56% were SS patients.
  • Its heartening to see this new real world data, which reinforces what weve seen previously in clinical trials.

Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

Monday, October 11, 2021 - 9:30pm

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the publication in the Annals of Hematology of a paper entitled Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data, which details statistical analyses comparing data from the Companys IMbark Phase 2 clinical trial to closely matched Real World Data (RWD).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the publication in the Annals of Hematology of a paper entitled Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data, which details statistical analyses comparing data from the Companys IMbark Phase 2 clinical trial to closely matched Real World Data (RWD).
  • The paper describes several statistical adjustment methods and multiple sensitivity analyses to improve comparability of the data set from the Companys IMbark Phase 2 trial and RWD to mimic the effect of a randomized trial.
  • While acknowledging the limitations of RWD analyses, the authors conclude that the results of these analyses warrant further prospective evaluation of imetelstat in a Phase 3 setting with OS as a primary endpoint.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society

Monday, October 4, 2021 - 12:00pm

The PK study was selected as a top clinical presentation at the meeting; additionally, the LANTERN Phase 2 manuscript won the ARS Annual Meeting 2021 Clinical Science Maurice Cottle Award.

Key Points: 
  • The PK study was selected as a top clinical presentation at the meeting; additionally, the LANTERN Phase 2 manuscript won the ARS Annual Meeting 2021 Clinical Science Maurice Cottle Award.
  • "A lack of strong rebound in CRS symptoms post-treatment and removal is very exciting, with potential long-term benefit for CRS patients.
  • "This release profile is exactly what I would want in an anti-inflammatory implant and the symptom improvement observed with LYR-210 is quite meaningful.
  • The LANTERN study, winner of the 2021 American Rhinology Society 2021 Maurice Cottle Award, has been published in the International Forum of Allergy & Rhinology.

IFIC and Pollara Release 2021 Canadian Mutual Fund and ETF Investor Survey

Wednesday, September 29, 2021 - 7:00pm

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The Investment Funds Institute of Canada (IFIC) and Pollara Strategic Insights today released the results of their annual Canadian Mutual Fund and Exchange-Traded Fund Investor Survey .

Key Points: 
  • TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The Investment Funds Institute of Canada (IFIC) and Pollara Strategic Insights today released the results of their annual Canadian Mutual Fund and Exchange-Traded Fund Investor Survey .
  • The survey this year included questions about the impact of the COVID-19 pandemic on Canadian mutual fund and ETF investors, and their ability to save and invest.
  • IFIC and Pollara have continued to adapt the survey to explore the new issues that matter to Canadian investors, which ultimately helps the industry better understand their needs, said Paul Bourque, President and CEO, IFIC.
  • There were significant increases in satisfaction with CRM2 statements in 2021 for both MF and ETF investors.

Imago BioSciences Announces Its Addition to the Russell 2000® Index

Monday, September 20, 2021 - 1:00pm

The inclusion of Imago BioSciences in the Russell 2000 Index marks a notable milestone following our successful IPO in July.

Key Points: 
  • The inclusion of Imago BioSciences in the Russell 2000 Index marks a notable milestone following our successful IPO in July.
  • The Russell 2000 Index measures the performance of the small-cap segment of the US equity market.
  • The Russell 2000 Index is a subset of the Russell 3000 Index representing approximately 10% of the total market capitalization of that index.
  • It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.

Missfresh Expands On-demand Live Seafood Delivery Business to 8 Cities in China

Thursday, September 16, 2021 - 1:29pm

BEIJING, Sept. 16, 2021 /PRNewswire/ --Missfresh Limited ("Missfresh" or the "Company") (NASDAQ: MF), an innovator and leader in China's neighborhood retail industry, is accelerating the rollout of its instant live seafood delivery (as quick as 30 minutes) to customers across China, having seen 20X growth in live seafood delivery sales since March.

Key Points: 
  • BEIJING, Sept. 16, 2021 /PRNewswire/ --Missfresh Limited ("Missfresh" or the "Company") (NASDAQ: MF), an innovator and leader in China's neighborhood retail industry, is accelerating the rollout of its instant live seafood delivery (as quick as 30 minutes) to customers across China, having seen 20X growth in live seafood delivery sales since March.
  • All seafood is delivered live in special packaging injected with oxygen, which keeps seafood fresh by minimizing external exposure, or customers can choose to have their purchases delivered pre-cleaned and ready to cook, eliminating the hassle of handling live seafood.
  • To ensure customer safety and satisfaction, all live seafood is carefully sourced and put through stringent safety checks.
  • Missfresh's approach to the live seafood supply and distribution chain stands out from some other retailers, who purchase and transport live seafood every few days, resulting in longer storage periods.

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

Thursday, September 9, 2021 - 9:05pm

WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that preclinical data for XTreo™ were published online in the peer-review journal, American Journal of Rhinology & Allergy. The manuscript titled, “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses,” can be accessed online here.

Key Points: 
  • The pharmacokinetics and drug release study evaluated the release of mometasone furoate (MF), a potent anti-inflammatory corticosteroid formulated into Lyras proprietary XTreo matrix, in a rabbit model.
  • XTreo is a powerful drug delivery platform that can target a precise dose of a therapeutic agent consistently over an extended period of time, up to many months.
  • Lyras XTreo technology platform enables precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.
  • The study evaluated the in vitro drug release and in vivo pharmacokinetics of novel XTreo MF matrices in a rabbit dorsal maxillary osteotomy model.

Global Membrane Bioreactor Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Friday, September 3, 2021 - 3:06pm

The "Membrane Bioreactor (MBR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Membrane Bioreactor (MBR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global membrane bioreactor (MBR) market exhibited moderate growth during 2015-2020.
  • Looking forward, the publisher expects the global membrane bioreactor (MBR) market to grow at a CAGR of 8% during 2021-2026.
  • A membrane bioreactor (MBR) is primarily used for industrial and municipal wastewater treatment.

Wastewater Treatment Services Market worth $71.6 billion by 2026 - Exclusive Report by MarketsandMarkets™

Thursday, August 26, 2021 - 1:30pm
Key Points: 
  • View Detailed Table of Content Here: https://www.marketsandmarkets.com/Market-Reports/wastewater-treatment-se...
    Growing population, expanding manufacturing industry, urbanization, and regulatory requirements are the major drivers of the wastewater treatment services market.
  • Growing population, expanding manufacturing industry, urbanization, and regulatory requirements are the major drivers of the wastewater treatment services market.
  • The APAC is the largest wastewater treatment services market with China being the major market which is expected to grow significantly.
  • The key players operating in the wastewater treatment services market are trying to increase their scope of services to address the increasing demand.